Navigation Links
Hemophiliacs Demand Justice

The Irish government said that it will not sue the US pharmaceutical companies which were accused of providing HIV and hepatitis C contaminated blood and plasma// products to more than 300 hemophiliacs.

Members of the hemophiliac society suffer from sporadic bleeding episodes that destroy joints and damage organs, requiring regular transfusions of blood-clotting products to survive. Tánaiste Mary Harney said that the government will not proceed with the case as it has received expert advice from the Irish attorney general that such a claim would not succeed. The Minister for Health said that although the Government acknowledges the terrible tragedy and wants to render all the help to the Irish Haemophilia Society. Statistics show that about 106 patients were infected with HIV and 221 patients with Hepatitis C.

But the Irish government said that money should be spent on improving the services to persons with haemophilia, including those infected with Hepatitis C and HIV rather than pursuing an inquiry against the pharmaceutical companies. The Irish Haemophilia Society on the other hand wants an enquiry in to this matter. It also claimed these US companies accepted and encouraged blood and plasma donations from high risk donors. Ms Harney mentioned that Armour Cutter Miles, Travenol-Baxter, Immuno International were the three US pharmaceutical companies which were accused in the scandal. Mr O’Mahony said that if legal action was taken in the States against these companies, and was successful then the Irish taxpayer could recoup all of the money spent on providing treatment, medical care and compensation.


'"/>




Page: 1

Related medicine news :

1. High Demand for a child vaccine
2. Demand for universal flu vaccination
3. Mentally Demanding Jobs Found To Reduce The Risk Of Alzheimer’
4. Research Fraud By Doctor – Probe Demanded
5. Drugs Manufacturers Capitalizing On The Surge In Demand For Bone Health Care
6. Bird Flu Likely To Reduce World Energy Demand
7. New Plastic Surgery Unit Set Up In Kolkata To Meet Ever-Increasing Consumer Demand
8. Sex Health Clinics Unable To Meet Increasing Demand
9. Bird Flu Scare Does Not Reduce Demand For Chicken
10. Demand For Diet Drugs On The Rise
11. High Demand For Circumcision In AIDS-Hit Swaziland
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Hemophiliacs Demand Justice

(Date:10/6/2008)...money, since side effects can affect length of sta...thDay News) -- Simple changes to hospital procedur...ren suffer while on opiates to relieve pain, a new...oration between 14 U.S. children,s hospitals, docu...aused by the pain relievers under these new proced...
(Date:10/6/2008).../PRNewswire-FirstCall/ -- HealthSouth,Corporation ...reviously,publicized investor meeting in New York ...8 at 8:30 a.m. EST at the Grand Hyatt New York, lo...g is as follows:, 8:00 a.m. Continental Break... Executive Officer -- HealthSouth Ove...
(Date:10/6/2008)...swire-USNewswire/ -- The United States has,interve...g that they,submitted false claims to Medicare ari...of sham durable medical equipment (DME) suppliers,...nies are McKesson Corporation,McKesson Medical-Su...,Golden Gate Ancillary LLC, Beverly Enterprises In...
(Date:10/6/2008)...wire/ -- Developed in collaboration with,Siemens(R...introducing,Revolutionary Breast Surface Imaging a...fice of Dr. Steve Laverson this week in Encinitas,...its kind, and is based on,breakthrough image captu...ive proprietary software. The XS-300(TM) platform ...
Breaking Medicine News(10 mins):Health News:Hospital Fixes Cut Opiate Errors in Kids 2Health News:HealthSouth to Hold Investor Meeting November 10, 2008 2Health News:U.S. Intervenes in False Claims Act Suit Against McKesson Corp. and Golden Horizons Nursing Homes 2Health News:Plan Your Breasts in 3-D 2
... weight apparently have to choose between their fa...oss , the supermodel Rachel Hunter has criticized ...n her recent weight loss. Hunter said that Hatche... her dangerously slim body. Hunter, who was once m...
...r to be who are obese and have associated diabetes...ies. Researchers examined the possible link betwee...tcomes // - primary caesarean delivery, pre-term b...LBW)- by racial, or ethnic group. Terry J. Rosenbe...
...rican Journal of Psychiatry had said that both Met...nificant changes in the brain structures that can ...ing new things, problem solving, paying attention ...lts are more if both the conditions happen simulta...
... hormone that can extend the lifespan of mice by a...gan showing signs of premature aging around 3 to 4...en compared to an average life span of 2 years. Th...to improving human longevity. The hormone is produ...
Other Medicine News:Health News:Hollywood Actress Hunter criticises Hatcher for weight loss. 2Health News:Obesity, diabetes in pregnant women affects babies 2Health News:Changes In Brain Structure From Methamphetamine Abuse And HIV Infection 2
(Date:10/7/2008)...ligen Therapeutics Inc.,today announced that in vi...dates were presented at the XXII International Com...ighlighted the candidates, efficacy in,several ani...se highlighted presentations, as well as several i...l the deep expertise and expanding,knowledge base ...
(Date:10/7/2008)...trolled Phase II Study Shows Statisticall...N VIEW, California, October 7 /- BN,I...se II data from the,therapeutic prostate cancer va...d as part of the recently entered partnership with...The results from the Phase II prospective randomiz...
(Date:10/7/2008)...for Use on the GeneXpert(R) ...wswire-FirstCall/ -- Cepheid (Nasdaq:,CPHD) today ...European CE,IVD Mark product under the European Di...e test delivers rapid detection of vanA and/or van...ancomycin-resistant,enterococci (VRE) -- one of th...
(Date:10/6/2008)...ll/ -- Pharmasset, Inc.,(Nasdaq: VRUS ) announces...mpany as Vice President of Investor Relations and ...sible for all investor relations,functions and wil...Leutzinger., Most recently, Dr. Smith was a Vice ...rgan Securities, and has been an analyst in the se...
Breaking Medicine Technology:In Vivo Data on Taligen Therapeutics' Pipeline Candidates Presented at the XXII International Complement Workshop 2In Vivo Data on Taligen Therapeutics' Pipeline Candidates Presented at the XXII International Complement Workshop 3In Vivo Data on Taligen Therapeutics' Pipeline Candidates Presented at the XXII International Complement Workshop 4BN ImmunoTherapeutics Announces Positive Mature Phase II Results From Newly Acquired Prostate Cancer Vaccine 2BN ImmunoTherapeutics Announces Positive Mature Phase II Results From Newly Acquired Prostate Cancer Vaccine 3BN ImmunoTherapeutics Announces Positive Mature Phase II Results From Newly Acquired Prostate Cancer Vaccine 4Cepheid Announces CE IVD Release of First On-Demand Test for van A/van B Genes Most Associated With Hospital-Acquired VRE Infection 2Cepheid Announces CE IVD Release of First On-Demand Test for van A/van B Genes Most Associated With Hospital-Acquired VRE Infection 3Cepheid Announces CE IVD Release of First On-Demand Test for van A/van B Genes Most Associated With Hospital-Acquired VRE Infection 4Richard E.T. Smith, Ph.D. Joins Pharmasset as Vice President of Investor Relations and Corporate Communications 2Richard E.T. Smith, Ph.D. Joins Pharmasset as Vice President of Investor Relations and Corporate Communications 3Circulation Publishes MERLIN TIMI 36 Data Showing Safety and Anti Arrhythmic Effects of Ranexa 28R 29 364 1Circulation Publishes MERLIN TIMI 36 Data Showing Safety and Anti Arrhythmic Effects of Ranexa 28R 29 364 2Circulation Publishes MERLIN TIMI 36 Data Showing Safety and Anti Arrhythmic Effects of Ranexa 28R 29 364 3Circulation Publishes MERLIN TIMI 36 Data Showing Safety and Anti Arrhythmic Effects of Ranexa 28R 29 364 4Inquiring minds want to know about cotton fleahoppers 252 1Inquiring minds want to know about cotton fleahoppers 252 2Inquiring minds want to know about cotton fleahoppers 252 3Exelixis Reports Encouraging Interim Data From a Phase 2 Trial of XL647 as First Line Therapy for Non Small Cell Lung Cancer 361 1Exelixis Reports Encouraging Interim Data From a Phase 2 Trial of XL647 as First Line Therapy for Non Small Cell Lung Cancer 361 2Exelixis Reports Encouraging Interim Data From a Phase 2 Trial of XL647 as First Line Therapy for Non Small Cell Lung Cancer 361 3Exelixis Reports Encouraging Interim Data From a Phase 2 Trial of XL647 as First Line Therapy for Non Small Cell Lung Cancer 361 4Saflink and IdentiPHI Announce Merger Agreement 251 1Saflink and IdentiPHI Announce Merger Agreement 251 2Saflink and IdentiPHI Announce Merger Agreement 251 3Saflink and IdentiPHI Announce Merger Agreement 251 4Saflink and IdentiPHI Announce Merger Agreement 251 5
...NESS WIRE)--Apr 3, 2007 -,Icagen, Inc. (NASDAQ: IC...ng of the independent Data Monitoring Committee,("...formerly,ICA-17043) for the treatment of sickle ce... trial be terminated because of the low,probabilit...mary,endpoint. In making their recommendation, the...
...Newswire-FirstCall/ --,SuperGen Inc. announced tod... American Association for Cancer Research,Annual M...tations,will focus on data concerning many of Supe...d tyrosine kinase inhibitor compound,MP470 and it...olved,in cancer cell drug resistance. Presentation...
Other Medicine Technology:Icagen Terminates Phase III ASSERT Study 2Icagen Terminates Phase III ASSERT Study 3SuperGen to Highlight Oncology Pipeline Data in Multiple,Presentations at AACR 2SuperGen to Highlight Oncology Pipeline Data in Multiple,Presentations at AACR 3SuperGen to Highlight Oncology Pipeline Data in Multiple,Presentations at AACR 4
IV Prep Swab Sticks are effective, easy to apply, dries quickly and reduces bacterial contaminations. They are ideal for preparation of the skin prior to a ventipuncture or injection.
Triad Plus Sterile Isopropyl Alcohol 70% USP Swabsticks are primarily used as a topical antiseptic prior to administering injections. They are gamma sterilized to meet AAMI/ANSI/ISO 11137 standar
Aplicare's Saturated Swabsticks are packaged in easy open, single-use foil-laminated pouches. Each 4 inch Swabstick is saturated with precisely the correct amount of solution. Each package is termina
BD Persist contains 70% alcohol and 10% povidone iodine formulated in a unique polymer base, forming a barrier on the skin. The barrier creates a protective environment for the povidone iodin
Medicine Products: